Long-term outcome of intravesical bacillus Calmette–Guérin therapy with maintenance for urinary bladder carcinoma in situ: About 47 cases

##plugins.themes.academic_pro.article.sidebar##

Published Sep 20, 2017
Download
pdf
Vol. 94 No. 12 (2016): Issue Dec 2016

##plugins.themes.academic_pro.article.main##

Sataa Sallami
Hassen Khouni
Mahmoud Ben Atta
Sana Abou El Makarim
Mohamed Bechir Zouari
Sami Ben Rhouma

Abstract

Introduction: Data concerning the efficacy of intravesical Bacillus Calmette-Guerin (BCG) on carcinoma in situ (CIS) of the bladder are limited.

Objectives: We analyzed long-term outcomes of instillation therapy with BCG to treat bladder CIS, evaluated its effectiveness and safety and searched for prognostic factors that could predict disease recurrence and progression.

Methods: Between March 1994 and December 2010, 47 patients (male: 40; female: 7) with median age of 59,5 years (range 40-76 years), diagnosed with bladder CIS underwent weekly BCG instillations (75 mg of Pasteur strain) for six weeks followed by 6 monthly instillations. Patients were collected from four different institututions.Proven bladder CIS diagnosis was made through random biopsy (n=19), macroscopic lesion (n=28) and urinary cytology (n=6).Primary, concomitant, and secondary CIS was found in 13 (27,6%), 28 (59,6%) and 6 (12,7%), patients, respectively.

Results:The median follow up period was 67.5 months (range 60-116 months).The recurence rates were 15,4%, 35,7% and 50% respectively in group I,II and III at 5 years follow-up. The overall complete response rate was 68%.The five-year progression-free survival rate was 87.2%.Several factors, such as age (<60 or >60 years), gender, previous transurethral resection and type of CIS, were examined by multivariate analysis to predict recurrence and progression. None of them was an independent prognostic factor.Bladder irritation symptoms were the main BCG adverse effects. There were no severe adverse effects requiring discontinuation of drug administration.Radical cystectomy was performed in 5 patients. Extravesical involvement was identified in only one patient. During follow-up period, none died of bladder cancer.

Conclusion: Therapy with BCG is remarkably effective and safe for primary CIS and concomittent CIS, which might be a prognostic factor. We didn’t find any significant risk factor. Recurrence and disease progression including extravesical involvement should be carefully monitored over the long-term after BCG therapy.

Keywords:

Bladder Cance, Carcinoma in situ, Bacillus Calmette-Guerin, Pasteur strain, instillation, adverse effect, Cytology, Cystoscopy, Prognosis, Progression, Recurrence

##plugins.themes.academic_pro.article.details##

References

  1. Epstein JI, Amin MB, Reuter VR, Mostofi FK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Am J Surg Pathol. 1998;22:1435-48.
  2. Zieger K, Jensen KM. Long-term risk of progression of carcinoma in situ of the bladder and impact of bacille Calmette-Guérin immunotherapy on the outcome. Scand J Urol Nephrol. 2011;45:411-8.
  3. Cheng L, Cheville JC, Neumann RM, et al. Survival of patients with carcinoma in situ of the urinary bladder. Cancer. 1999;85:2469-74.
  4. Lamm DL. Carcinoma in situ. Urol Clin North Am. 1992;19:499-508. 5) Witjes JA. Bladder carcinoma in situ in 2003: state of the art. Eur Urol. 2004;45:142-6
  5. Ovesen H, Poulsen AL, Steven K. Intravesical Bacillus Calmette-Guérin with the Danish strain for treatment of carcinoma in situ of the bladder. Br J Urol. 1993;72:744-8.
  6. Wolf H, Melsen F, Pedersen SE, Nielsen KT. Natural history of carcinoma in situ of the urinary bladder. Scand J Urol Nephrol Suppl. 1994;157:147-51.
  7. Mostofi FK. International histologic classification of tumors. A report by the Executive Committee of the International Council of Societies of Pathology. Cancer. 1974;33:1480-4.
  8. Kurth KH, Schellhammer PF, Okajima E, et al. Current methods of assessing and treating carcinoma in situ of the bladder with or without involvement of the prostatic urethra. Int J Urol. 1995;2:8-22.
  9. Andius P, Damm O, Holmäng S. Prognostic factors in patients with carcinoma in situ treated with intravesical bacille Calmette-Guérin. Scand J Urol Nephrol. 2004;38:285-90
  10. Norming U, Nyman CR, Tribukait B. Comparative histopathology and deoxyribonucleic acid flow cytometry of random mucosal biopsies in untreated bladder carcinoma. J Urol. 1991;145:1164-8.
  11. Wolf H, Olsen PR, Fischer A, Højgaard K. Urothelial atypia concomitant with primary bladder tumour. Incidence in a consecutive series of 500 unselected patients. Scand J Urol Nephrol. 1987;21:33-8.
  12. Glas AS, Roos D, Deutekom M, Zwinderman AH, Bossuyt PM, Kurth KH. Tumor markers in the diagnosis of primary bladder cancer. A systematic review. J Urol. 2003 ;169:1975-82.
  13. Lerner SP, Colen J, Shen S. Prostatic biology, histologic patterns and clinical consequences of transitional cell carcinoma. Curr Opin Urol. 2008;18:508-12.
  14. Demir MA, Ryd W, Aldenborg F, Holmang S. Cytopathological expression of different types of urothelial carcinoma in situ in urinary bladder washings. BJU Int. 2003;92:906-10.
  15. Lerner SP, Liu H, Wu MF, Thomas YK, Witjes JA. Fluorescence and white light cystoscopy for detection of carcinoma in situ of the urinary bladder. Urol Oncol. 2012;30:285-9.
  16. Schmidbauer J, Witjes F, Schmeller N, et al. Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J Urol. 2004;171:135-8.
  17. Fradet Y, Grossman HB, Gomella L, et al. A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. J Urol. 2007;178:68-73.
  18. Colombo R, Naspro R, Bellinzoni P, et al. Photodynamic diagnosis for follow-up of carcinoma in situ of the bladder. Ther Clin Risk Manag. 2007;3:1003-7.
  19. Mian C, Lodde M, Comploj E, et al. The value of the ImmunoCyt/uCyt+ test in the detection and follow-up of carcinoma in situ of the urinary bladder. Anticancer Res. 2005;25:3641-4.
  20. Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superï¬cial bladder tumors. J Urol. 1976;116:180-3.
  21. Lamm DL. BCG immunotherapy for transitional-cell carcinoma in situ of the bladder. Oncology (Williston Park). 1995;9:947-65.
  22. Akaza H, Hinotsu S, Aso Y, Kakizoe T, Koiso K. Bacillus Calmette-Guérin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder. Four-year results. The Bladder Cancer BCG Study Group. Cancer. 1995;75:552-9.
  23. Harland SJ, Charig CR, Highman W, Parkinson MC, Riddle PR. Outcome in carcinoma in situ of bladder treated with intravesical bacille Calmette-Guerin. Br J Urol. 1992;70: 271-5.
  24. De Jager R, Guinan P, Lamm D, et al. Long-term complete remission in bladder carcinoma in situ with intravesical TICE bacillus Calmette Guerin. Overview analysis of six phase II clinical trials. Urology. 1991;38:507-13.
  25. Jakse G, Hall R, Bono A, et al. BCG treatment in Tis of the urinary bladder, results of the EORTC Protocol 30861. EORTC GU Group. Prog Clin Biol Res. 1992;378:69-74.
  26. Talic RF, Hargreave TB, Bishop MC, Kirk D, Prescott S. Intravesical Evans bacille Calmette-Guerin for carcinoma in situ of the urinary bladder. Scottish Urological Oncology Group. Br J Urol. 1994;73:645-8.
  27. Nadler RB, Catalona WJ, Hudson MA, Ratliff TL. Durability of the tumor-free response for intravesical bacillus Calmette-Guerin therapy. J Urol. 1994;152:367-73.
  28. Sylvester RJ, van der Meijden AP, Witjes JA, Kurth K. Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol. 2005;174:86-91.
  29. Kaasinen E, Wijkström H, Malmström PU, et al. Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a nordic study. Eur Urol. 2003;43:637-45.
  30. Oosterlinck W, Kirkali Z, Sylvester R, et al. Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTC genito-urinary group randomized phase 2 trial (30993). Eur Urol. 2011;59:438-46.
  31. Smith JA Jr, Labasky RF, Cockett AT, Fracchia JA, Montie JE, Rowland RG. Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and TIS). The American Urological Association. J Urol. 1999;162:1697-701.
  32. Cookson MS, Herr HW, Zhang ZF, Soloway S, Sogani PC, Fair WR. The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol. 1997;158:62-7.
  33. Jakse G, Hall R, Bono A, et al. Intravesical BCG in patients with carcinoma in situ of the urinary bladder: long-term results of EORTC GU Group phase II protocol 30861. Eur Urol. 2001;40:144-50.
  34. Lamm D, Herr H, Jakse G, et al. Updated concepts and treatment of carcinoma in situ. Urol Oncol. 1998;4:130-8.
  35. Griffiths TR, Charlton M, Neal DE, Powell PH. Treatment of carcinoma in situ with intravesical bacillus Calmette-Guerin without maintenance. J Urol. 2002;167:2408-12.
  36. Chade DC, Shariat SF, Adamy A, et al. Clinical outcome of primary versus secondary bladder carcinoma in situ. J Urol. 2010;184:464-9.
  37. Murphy WM, Busch C, Algaba F. Intraepithelial lesions of urinary bladder: morphologic considerations. Scand J Urol Nephrol Suppl. 2000;20:67-81.
  38. Herr HW. Extravesical tumor relapse in patients with superï¬cial bladder tumors. J Clin Oncol.1998;16:1099-102.
  39. Sylvester RJ, van der Meijden A, Witjes JA, et al. High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder. Urology. 2005;66:90-107.
  40. Takashi M, Katsuno S, Yuba H, Ohshima S, Wakai K, Ohno Y. Possible factors affecting response to intravesical bacillus Calmette-Guerin (Tokyo 172 strain) therapy for carcinoma in situ of the bladder: a multivariate analysis. Int Urol Nephrol. 1998; 30: 713-22.
  41. Takenaka A, Yamada Y, Miyake H, Hara I, Fujisawa M. Clinical outcomes of bacillus Calmette-Guérin instillation therapy for carcinoma in situ of urinary bladder. Int J Urol. 2008;15:309-13.
  42. Orozco RE, Martin AA, Murphy WM. Carcinoma in situ of the urinary bladder. Clues to host involvement in human carcinogenesis. Cancer. 1994;74:115-22.
  43. Ovesen H, Horn T, Steven K. Long-term efficacy of intravesical bacillus Calmette-Guerin for carcinoma in situ: relationship of progression to histological response and p53 nuclear accumulation. J Urol. 1997;157:1655-9.
  44. Bowyer L, Hall RR, Reading J, Marsh MM. The persistence of bacille Calmette-Guérin in the bladder after intravesical treatment for bladder cancer. Br J Urol. 1995;75:188-92.
  45. Hayakawa N, Kikuchi E, Mikami S, Matsumoto K, Miyajima A, Oya M. The clinical impact of the classification of carcinoma in situ on tumor recurrence and their clinical course in patients with bladder tumor. Jpn J Clin Oncol. 2011;41:424-9.
  46. Mugiya S, Ozono S, Nagata M, et al. Long-term outcome of a low-dose intravesical bacillus Calmette-Guerin therapy for carcinoma in situ of the bladder: results after six successive instillations of 40 mg BCG. Jpn J Clin Oncol. 2005;35:395-9.
  47. Van Gils-Gielen RJ, Witjes WP, Caris CT, Debruyne FM, Witjes JA, Oosterhof GO. Risk factors in carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group. Urology. 1995;45:581-6.
  48. Orsola A, Palou J, Xavier B, Algaba F, Salvador J, Vicente J. Primary bladder carcinoma in situ: assessment of early BCG response as a prognostic factor. Eur Urol. 1998;33:457-63.
  49. Shariat SF, Kim J, Raptidis G, Ayala GE, Lerner SP. Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder. Urology. 2003;61:1140-5.
  50. Shariat SF, Pahlavan S, Baseman AG, et al. E-cadherin expression predicts clinical outcome in carcinoma in situ of the urinary bladder. Urology. 2001;57:60-5.
  51. Lamm DL, van der Meijden PM, Morales A, et al. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol. 1992;147:596-600.
  52. Ayed M, Ben Hassine L, Ben Slama R, et al. Results of BCG in the treatment of pTa and pT1 bladder tumors. Evaluation of a long protocol using 75 mg of Pasteur strain BCG. Prog Urol. 1998;8:206-10.
  53. Lamm DL. Preventing progression and improving survival with BCG maintenance. Eur Urol. 2000;37 Suppl 1:9-15.
  54. Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol. 2000;163:1124-9.
  55. Sylvester RJ, van der MEIJDEN AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol. 2002;168:1964-70.
  56. van der Meijden AP, Sylvester R, Oosterlinck W, et al. EAU guidelines on the diagnosis and treatment of urothelial carcinoma in situ. Eur Urol. 2005;48:363-71.
  57. Hall MC, Chang SS, Dalbagni G, et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol. 2007;178:2314-30.
  58. Koga H, Kuroda M, Kudo S, et al. Adverse drug reactions of intravesical bacillus Calmette-Guerin instillation and risk factors of the development of adverse drug reactions in superficial cancer and carcinoma in situ of the bladder. Int J Urol. 2005;12:145-51.
  59. Witjes JA. Management of BCG failures in superficial bladder cancer: a review. Eur Urol. 2006;49:790-7.
  60. 61) Alfred Witjes J, Hendricksen K, Gofrit O, Risi O, Nativ O. Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo working party. World J Urol. 2009;27:319-24.